American Society of Hirudotherapy

Oral Anticoagulation

Review published in Deutsches Arzteblatt international (2018)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewClinical LiteratureDrug DevelopmentAltiok et al. · Deutsches Arzteblatt international, 2018

Abstract

BACKGROUND: Much new evidence on oral anticoagulation has come to light in recent years. Non-vitamin-K-dependent oral anti- coagulants (NOAC) have been developed and have been introduced into clinical practice. In this review, we present the current state of the evidence on anticoagulation for various indications with vitamin K antagonists (VKA) and with NOAC. METHODS: This review is based on pertinent articles retrieved by a selective search in PubMed (search terms: anticoagulation, atrial fibrillation, prosthetic valve, thrombosis, pulmonary embolism) and on specialty society recommendations and relevant guidelines from the years 2000-2018. RESULTS: The main indications for oral anticoagulation are atrial fibrillation, venous thromboembolism, and status post heart valve replacement. In patients with atrial fibrillation and without valvular heart disease, anticoagulation is recommended for men with a CHA2DS2-VASc score ≥ 1 and for women with a score ≥ 2. NOAC for this indication are associated with a marginally lower rate of stroke than VKA (3.5% vs. 3.8%, number needed to treat [NNT] = 333) as well as a lower rate of major hemorrhage (5.1% vs. 6.2%, NNT = 91). NOAC are contraindicated for patients with mechanical heart valves. Anticoagulation with VKA can be predictably antagonized. Among the various types of NOAC, the anticoagulant effect of dabigatran can be safely antagonized with an antidote; no specific antidote is yet available for apixaban, rivaroxaban, or edoxaban. CONCLUSION: The evidence base for anticoagulation over a time frame of several years is inadequate at present, and direct comparative data for the different types of NOAC are not yet available.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAdministration, OralAnticoagulantsAtrial FibrillationHeart Valve ProsthesisHumansRisk AssessmentVenous ThromboembolismVitamin K

Summary

This review of oral anticoagulation with vitamin K antagonists and non-vitamin-K antagonists covers atrial fibrillation, venous thromboembolism and heart valve replacement, finding NOACs marginally better than VKA for stroke and major hemorrhage in nonvalvular atrial fibrillation but contraindicated with mechanical valves.

Why This Matters for Hirudotherapy

This review evaluated the current state of evidence for oral anticoagulation, specifically comparing vitamin K antagonists (VKAs) and non-vitamin-K-dependent oral anticoagulants (NOACs) across various cardiovascular indications. For the American Society of Hirudotherapy, this article provides important background on systemic anticoagulant therapies, which conceptually parallel the potent localized anticoagulant effects of leech salivary components like hirudin. Reviewing the bleeding risks and therapeutic mechanisms of standard oral anticoagulants helps define the clinical landscape in which leech-derived therapies might be understood or contrasted. However, the abstract focuses exclusively on conventional pharmacology and does not mention leeches, hirudotherapy, or the leech secretome, representing only indirect thematic relevance.

Citation

Reference (Vancouver style)

Altiok E, Marx N. Oral Anticoagulation. Dtsch Arztebl Int. 2018;115(46):776-783. doi:10.3238/arztebl.2018.0776. PMID: 30602410

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.